BioNexus Taps Governance Czar to Steer Subsidiary's High-Tech Pivot

KUALA LUMPUR, Malaysia – February 23, 2026 – BioNexus Gene Lab Corp. (NASDAQ: BGLC) has initiated a significant strategic overhaul of its wholly-owned subsidiary, Chemrex Corporation Sdn. Bhd., appointing distinguished governance and economic strategist Matthew L. Barsing as its new Chairman. The move, which streamlines the subsidiary’s board to just two members, is being positioned as a critical step in preparing the legacy industrial supplier for a potential pivot into high-growth sectors like biotechnology and advanced manufacturing.

The restructuring centralizes financial oversight and aligns Chemrex with the parent company's stringent reporting and capital review standards. It signals a decisive shift for BioNexus, a company aggressively building a cross-border precision medicine and AI-healthcare platform, as it looks to repurpose all assets to serve its core technological vision. While Chemrex remains a profitable entity, its future may look drastically different from its past.

A New Mandate for a Legacy Asset

Acquired by BioNexus at the end of 2020, Chemrex Corporation has long operated as a major supplier of chemical and fiberglass raw materials for the composite industry. Its products, including polyester resins, catalysts, and Kevlar fabric, are essential components for sectors ranging from automotive and construction to medical equipment across Southeast Asia and Australia. In 2019, the year before its acquisition, Chemrex posted revenues of approximately $15.42 million.

However, this industrial focus stands in stark contrast to the cutting-edge direction of its parent company. BioNexus is now openly evaluating a radical transformation for Chemrex. The potential new paths under consideration include biotechnology-focused development, advanced manufacturing, or healthcare-related infrastructure—all areas that align directly with BioNexus's broader ecosystem strategy. This restructuring is the first tangible action following a staged capital allocation framework approved in July 2025, designed specifically to fund such operational upgrades, contingent on market conditions and strategic fit.

The appointment of a new chairman and a streamlined board is designed to create a nimble and accountable leadership structure capable of rigorously assessing these capital-intensive opportunities and, if approved, executing a complex business transformation.

Governance as the Catalyst for Growth

The choice of Matthew L. Barsing as Chairman speaks volumes about BioNexus's methodology. Barsing is not a veteran of the chemical supply industry; rather, he brings over 25 years of experience as a governance-focused advisor and economic strategist. His resume is notable for his tenure as Head of Foreign Direct Investment at Malaysia’s Multimedia Development Corporation (MDeC), now MDEC, where he was instrumental in securing over RM5.3 billion in global investment projects for the country.

His expertise lies in navigating complex regulatory landscapes, coordinating with government agencies, and implementing disciplined governance frameworks—skills essential for any company venturing into highly regulated sectors like biotechnology and healthcare in Malaysia. His current role as a Director at EPS Consultants focuses on cross-border operational risk, and his mentorship at the venture capital firm Orbit Startups gives him insight into the needs of emerging technology companies.

"Chemrex represents a strategic platform within our broader technology ecosystem," said Sam Tan, Chief Executive Officer of BioNexus, in a statement. "The Board’s capital allocation framework provides flexibility to evaluate growth-oriented initiatives while maintaining prudent oversight and disciplined capital management."

Barsing's own comments reinforce this focus on process over a predetermined outcome. "Our focus is governance, accountability, and structured execution," he stated. "We will continue to assess strategic opportunities that align with BioNexus’s long-term objectives while ensuring appropriate regulatory awareness and capital discipline."

BioNexus's Broader Ambitions in Asian Biotech

The strategic repositioning of Chemrex is not an isolated event. It is a key piece in a larger, ambitious puzzle that BioNexus has been assembling across Asia. The company is aggressively expanding its footprint in precision diagnostics and AI-integrated healthcare, aiming to become a dominant force in the region's rapidly modernizing medical landscape.

Recent months have seen a flurry of activity underscoring this strategy. In December 2025, BioNexus acquired a 15% equity stake in Fidelion Diagnostics, securing exclusive commercial rights in Southeast Asia for the VitaGuard™ Minimal Residual Disease (MRD) oncology platform. That same month, it secured a massive $500 million equity facility from ARC Group International to fund its expansion into diagnostics, contract development and manufacturing organization (CDMO) services, and therapeutic commercialization.

More recently, in February 2026, the company announced its intent to lead a $10 million financing round for BirchBioMed Inc. to commercialize a novel topical medical platform in the region. These moves demonstrate a clear pattern: BioNexus is using strategic investments, partnerships, and now internal restructuring to build a comprehensive, vertically integrated biotech powerhouse. This strategy is well-timed, as it aligns with the Malaysian government's own push to develop its bio-innovation sector through its National Biotechnology Policy 2.0.

Navigating the Path from Chemicals to Cutting-Edge Tech

Transforming an industrial chemical supplier into a high-tech biotechnology or manufacturing hub is an undertaking fraught with risk and complexity. It requires not only significant capital but also a fundamental shift in talent, operations, and corporate culture. The new governance structure at Chemrex, led by Barsing, is explicitly designed to manage these risks through a disciplined and analytical approach.

The company has been transparent that no definitive commitments have been made regarding the final scope or timing of any initiative. The current phase is one of pure evaluation. This cautious approach is prudent, particularly given the financial pressures that can accompany rapid growth. While BioNexus reported a strong cash position at the end of 2024, public filings from 2025 noted the company was burning through cash and had executed a reverse stock split to maintain its Nasdaq listing, underscoring the importance of making sound capital allocation decisions.

With a strengthened board and a clear mandate for disciplined evaluation, the Chemrex subsidiary now stands at a crossroads. The leadership team is tasked with determining the most valuable and viable path forward, a decision that will significantly shape the future of both Chemrex and BioNexus's broader strategic ambitions in Asia. The market will be watching closely for further updates as this strategic evaluation advances and key milestones are achieved.